1
|
Ceccanti C, Davini A, Lo Piccolo E, Lauria G, Rossi V, Ruffini Castiglione M, Spanò C, Bottega S, Guidi L, Landi M. Polyethylene microplastics alter root functionality and affect strawberry plant physiology and fruit quality traits. J Hazard Mater 2024; 470:134164. [PMID: 38583200 DOI: 10.1016/j.jhazmat.2024.134164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/23/2023] [Revised: 02/24/2024] [Accepted: 03/27/2024] [Indexed: 04/09/2024]
Abstract
Strawberry, a globally popular crop whose fruit are known for their taste and health benefits, were used to evaluate the effects of polyethylene microplastics (PE-MPs) on plant physiology and fruit quality. Plants were grown in 2-L pots with natural soil mixed with PE-MPs at two concentrations (0.2% and 0.02%; w/w) and sizes (⌀ 35 and 125 µm). Plant physiological responses, root histochemical and anatomical analyses as well as fruit biometric and quality features were conducted. Plants subjected to ⌀ 35 µm/0.2% PE-MPs exhibited the most severe effects in terms of CO2 assimilation due to stomatal limitations, along with the highest level of oxidative stress in roots. Though no differences were observed in plant biomass, the impact on fruit quality traits was severe in ⌀ 35 µm/0.2% MPs treatment resulting in a drop in fruit weight (-42%), soluble solid (-10%) and anthocyanin contents (-25%). The smallest sized PE-MPs, adsorbed on the root surface, impaired plant water status by damaging the radical apparatus, which finally resulted in alteration of plant physiology and fruit quality. Further research is required to determine if these alterations also occur with other MPs and to understand more deeply the MPs influence on fruit physio-chemistry.
Collapse
Affiliation(s)
- C Ceccanti
- Department of Agriculture, Food and Environment, University of Pisa, via del Borghetto, 80, 56124 Pisa, Italy
| | - A Davini
- Department of Agriculture, Food and Environment, University of Pisa, via del Borghetto, 80, 56124 Pisa, Italy
| | - E Lo Piccolo
- Department of Agriculture, Food, Environment and Forestry, University of Florence, viale delle Idee 30, 50019 Sesto Fiorentino, Firenze, Italy.
| | - G Lauria
- Department of Agriculture, Food and Environment, University of Pisa, via del Borghetto, 80, 56124 Pisa, Italy
| | - V Rossi
- Department of Agriculture, Food and Environment, University of Pisa, via del Borghetto, 80, 56124 Pisa, Italy
| | - M Ruffini Castiglione
- Department of Biology, University of Pisa, via Luca Ghini, 13, 56126 Pisa, Italy; CIRSEC, Centre for Climate Change Impact, University of Pisa, Pisa, Italy
| | - C Spanò
- Department of Biology, University of Pisa, via Luca Ghini, 13, 56126 Pisa, Italy; CIRSEC, Centre for Climate Change Impact, University of Pisa, Pisa, Italy
| | - S Bottega
- Department of Biology, University of Pisa, via Luca Ghini, 13, 56126 Pisa, Italy
| | - L Guidi
- Department of Agriculture, Food and Environment, University of Pisa, via del Borghetto, 80, 56124 Pisa, Italy; CIRSEC, Centre for Climate Change Impact, University of Pisa, Pisa, Italy
| | - M Landi
- Department of Agriculture, Food and Environment, University of Pisa, via del Borghetto, 80, 56124 Pisa, Italy; CIRSEC, Centre for Climate Change Impact, University of Pisa, Pisa, Italy.
| |
Collapse
|
2
|
Meloni A, Pistoia L, Putti MC, Longo F, Corigliano E, Ricchi P, Rossi V, Casini T, Righi R, Renne S, Peritore G, Barbuto L, Positano V, Cademartiri F. Pancreatic iron in pediatric transfusion-dependent beta-thalassemia patients: A longitudinal MRI study. Pediatr Blood Cancer 2024; 71:e30923. [PMID: 38385860 DOI: 10.1002/pbc.30923] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Revised: 02/02/2024] [Accepted: 02/08/2024] [Indexed: 02/23/2024]
Abstract
BACKGROUND In pediatric transfusion-dependent thalassemia (TDT) patients, we evaluated the prevalence, pattern, and clinical associations of pancreatic siderosis and the changes in pancreatic iron levels and their association with baseline and changes in total body iron balance. PROCEDURE We considered 86 pediatric TDT patients consecutively enrolled in the Extension-Myocardial Iron Overload in Thalassemia Network. Iron overload (IO) was quantified by R2* magnetic resonance imaging (MRI). RESULTS Sixty-three (73%) patients had pancreatic IO (R2* > 38 Hz). Global pancreas R2* values were significantly correlated with mean serum ferritin levels, MRI liver iron concentration (LIC) values, and global heart R2* values. Global pancreas R2* values were significantly higher in patients with altered versus normal glucose metabolism. Thirty-one patients also performed the follow-up MRI at 18 ± 3 months. Higher pancreatic R2* values were detected at the follow-up, but the difference versus the baseline MRI was not significant. The 20% of patients with baseline pancreatic IO showed no pancreatic IO at the follow-up. The 46% of patients without baseline pancreatic IO developed pancreatic siderosis. The changes in global pancreas R2* between the two MRIs were not correlated with baseline serum ferritin levels, baseline, final, and changes in MRI LIC values, or baseline pancreatic iron levels. CONCLUSIONS In children with TDT, pancreatic siderosis is a frequent finding associated with hepatic siderosis and represents a risk factor for myocardial siderosis and alterations of glucose metabolism. Iron removal from the pancreas is exceptionally challenging and independent from hepatic iron status.
Collapse
Affiliation(s)
- Antonella Meloni
- Bioengineering Unit, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy
- Department of Radiology, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy
| | - Laura Pistoia
- Department of Radiology, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy
- U.O.C. Ricerca Clinica, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy
| | - Maria Caterina Putti
- Dipartimento della Salute della Donna e del Bambino, Clinica di Emato-Oncologia Pediatrica, Azienda Ospedaliero-Università di Padova, Padua, Italy
| | - Filomena Longo
- Unità Operativa Day Hospital della Talassemia e delle Emoglobinopatie, Azienda Ospedaliero-Universitaria "S. Anna,", Cona, Ferrara, Italy
| | | | - Paolo Ricchi
- U.O.S.D. Malattie Rare del Globulo Rosso, Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli", Naples, Italy
| | | | - Tommaso Casini
- SOC Oncologia, Ematologia e Trapianto di Cellule Staminali Emopoietiche, Meyer Children's Hospital IRCCS, Florence, Italy
| | - Riccardo Righi
- Diagnostica per Immagini e Radiologia Interventistica, Ospedale del Delta, Lagosanto, Ferrara, Italy
| | - Stefania Renne
- Struttura Complessa di Cardioradiologia-UTIC, Presidio Ospedaliero "Giovanni Paolo II,", Lamezia Terme, Italy
| | - Giuseppe Peritore
- Unità Operativa Complessa di Radiologia, "ARNAS" Civico, Di Cristina Benfratelli, Palermo, Italy
| | - Luigi Barbuto
- U.O.C. Radiologia Generale e di Pronto Soccorso, Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli", Naples, Italy
| | - Vincenzo Positano
- Bioengineering Unit, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy
- Department of Radiology, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy
| | - Filippo Cademartiri
- Department of Radiology, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy
| |
Collapse
|
3
|
Altieri V, Rossi V, Fedele G. Integration of mathematical modeling and target-based application of biocontrol agents for the control of Botrytis cinerea in vineyards. Pest Manag Sci 2024. [PMID: 38634563 DOI: 10.1002/ps.8140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/08/2024] [Revised: 03/25/2024] [Accepted: 04/17/2024] [Indexed: 04/19/2024]
Abstract
BACKGROUND Biocontrol agents (BCAs) are alternatives to synthetic fungicides with low risk to the environment and human health. Although several studies on the biocontrol of gray mold in vineyards have been performed, it is necessary to improve the usage of BCAs in fields conditions. Therefore, in the present study, BCAs were used both in calendar- (based on four growth stages (GSs), i.e., flowering, pre-bunch closure, veraison, and before harvest) and predictive model-based strategies (only when Botrytis cinerea infection risk was predicted by the model). The BCAs applied during the seasons were selected considering the grapevine GSs. Treatments performed with BCAs were compared with synthetic fungicide treatments and an untreated control. The trials were conducted in three experimental vineyards with four epidemics. To evaluate the level of gray mold control of each treatment, disease severity was assessed at harvest and the presence of latent infection was evaluated. RESULTS The integrative use of the predictive model and BCAs provided satisfactory levels of gray mold control, with gray mold severity levels significantly lower (P < 0.001) than those of the untreated control, which had severity values (<7%) similar to those observed with synthetic fungicides following both calendar and model-based strategies. CONCLUSIONS The integrative use of the predictive model and BCAs represents a valid alternative to conventional methods of gray mold control in vineyards, with more than 75% reduction in fungicide usage. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- V Altieri
- DiProVeS, Università Cattolica del Sacro Cuore di Piacenza, via Emilia Parmense 84, 29122, Piacenza, Italy
| | - V Rossi
- DiProVeS, Università Cattolica del Sacro Cuore di Piacenza, via Emilia Parmense 84, 29122, Piacenza, Italy
| | - G Fedele
- DiProVeS, Università Cattolica del Sacro Cuore di Piacenza, via Emilia Parmense 84, 29122, Piacenza, Italy
| |
Collapse
|
4
|
Meloni A, Pistoia L, Ricchi P, Bagnato S, Longo F, Messina G, Bagnato S, Rossi V, Renne S, Righi R, Fina P, Positano V, Cademartiri F. Impact of genotype on multi-organ iron and complications in patients with non-transfusion-dependent β-thalassemia intermedia. Ann Hematol 2024:10.1007/s00277-024-05741-9. [PMID: 38581547 DOI: 10.1007/s00277-024-05741-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Accepted: 03/30/2024] [Indexed: 04/08/2024]
Abstract
We evaluated the impact of the genotype on clinical and hematochemical features, hepatic and cardiac iron levels, and endocrine, hepatic, and cardiovascular complications in non-transfusion-dependent (NTD) β-thalassemia intermedia (TI) patients. Sixty patients (39.09 ± 11.11 years, 29 females) consecutively enrolled in the Myocardial Iron Overload in Thalassemia project underwent Magnetic Resonance Imaging to quantify iron overload, biventricular function parameters, and atrial areas and to detect replacement myocardial fibrosis. Three groups of patients were identified: homozygous β+ (N = 18), heterozygous β0β+ (N = 22), and homozygous β0 (N = 20). The groups were homogeneous for sex, age, splenectomy, hematochemical parameters, chelation therapy, and iron levels. The homozygous β° genotype was associated with significantly higher biventricular end-diastolic and end-systolic volume indexes and bi-atrial area indexes. No difference was detected in biventricular ejection fractions or myocardial fibrosis. Extramedullary hematopoiesis and leg ulcers were significantly more frequent in the homozygous β° group compared to the homozygous β+ group. No association was detected between genotype and liver cirrhosis, hypogonadism, hypothyroidism, osteoporosis, heart failure, arrhythmias, and pulmonary hypertension. Heart remodelling related to a high cardiac output state cardiomyopathy, extramedullary hematopoiesis, and leg ulcers were more pronounced in patients with the homozygous β° genotype compared to the other genotypes analyzed. The knowledge of the genotype can assist in the clinical management of NTD β-TI patients.
Collapse
Affiliation(s)
- Antonella Meloni
- Department of Radiology, Fondazione G. Monasterio CNR-Regione Toscana, Via Moruzzi, 1, 56124, Pisa, Italy
- U.O.C. Bioingegneria, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy
| | - Laura Pistoia
- Department of Radiology, Fondazione G. Monasterio CNR-Regione Toscana, Via Moruzzi, 1, 56124, Pisa, Italy
- U.O.C. Ricerca Clinica, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy
| | - Paolo Ricchi
- U.O.S.D. Malattie Rare del Globulo Rosso, Azienda Ospedaliera Di Rilievo Nazionale "A. Cardarelli", Naples, Italy
| | - Sergio Bagnato
- Ematologia Microcitemia, Ospedale San Giovanni di Dio - ASP Crotone, Crotone, Italy
| | - Filomena Longo
- Unità Operativa Day Hospital Della Talassemia E Delle Emoglobinopatie, Azienda Ospedaliero-Universitaria "S. Anna", Cona, FE, Italy
| | - Giuseppe Messina
- Centro Microcitemie, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy
| | - Sabrina Bagnato
- U.O.S. Di Talassemia, Presidio Ospedaliero Lentini - ASP 8 Siracusa, Lentini, SR, Italy
| | | | - Stefania Renne
- Struttura Complessa Di Cardioradiologia-UTIC, Presidio Ospedaliero "Giovanni Paolo II", Lamezia Terme, Italy
| | - Riccardo Righi
- Diagnostica Per Immagini E Radiologia Interventistica, Ospedale del Delta, Lagosanto, FE, Italy
| | - Priscilla Fina
- Unità Operativa Complessa Diagnostica Per Immagini, Ospedale "Sandro Pertini", Rome, Italy
| | - Vincenzo Positano
- Department of Radiology, Fondazione G. Monasterio CNR-Regione Toscana, Via Moruzzi, 1, 56124, Pisa, Italy
- U.O.C. Bioingegneria, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy
| | - Filippo Cademartiri
- Department of Radiology, Fondazione G. Monasterio CNR-Regione Toscana, Via Moruzzi, 1, 56124, Pisa, Italy.
| |
Collapse
|
5
|
Gennari A, Brain E, De Censi A, Nanni O, Wuerstlein R, Frassoldati A, Cortes J, Rossi V, Palleschi M, Alberini JL, Matteucci F, Piccardo A, Sacchetti G, Ilhan H, D'Avanzo F, Ruffilli B, Nardin S, Monti M, Puntoni M, Fontana V, Boni L, Harbeck N. Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): Pilot study with 18F-Fluoroestradiol (18F-FES) CT/PET. Ann Oncol 2024:S0923-7534(24)00057-7. [PMID: 38423389 DOI: 10.1016/j.annonc.2024.02.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 01/15/2024] [Accepted: 02/20/2024] [Indexed: 03/02/2024] Open
Abstract
BACKGROUND 18F-FES PET/CT is considered an accurate diagnostic tool to determine whole-body endocrine responsiveness. In the ET-FES trial, we evaluated 18F-FES PET/CT as a predictive tool in ER+/HER2- metastatic breast cancer (MBC). METHODS Eligible patients underwent a 18F-FES PET/CT at baseline. Patients with SUV≥2 received single agent ET until PD; patients with SUV<2 were randomized to single agent ET (Arm A) or chemotherapy (CT) (Arm B). Primary objective was to compare the activity of first line ET versus CT in patients with 18F-FES SUV <2. RESULTS Overall, 147 patients were enrolled; 117 presented with 18F-FES SUV≥2 and received ET; 30 pts with SUV<2 were randomized to ET or CT. After a median follow up of 62.4 months, 104 patients (73.2%) had disease progression and 53 died (37.3%). Median PFS was 12.4 months (95%CI 3.1-59.6) in patients with SUV <2 randomised to Arm A versus 23.0 months (95%CI 7.7-30.0) in Arm B, (HR = 0.71, 95%CI 0.3 - 1.7); median PFS was 18.0 months (95%CI 11.2-23.1) in patients with SUV≥2 treated with ET. Median OS was 28.2 months (95%CI 14.2-NE) in patients with SUV <2 randomized to ET (Arm A) versus 52.8 months (95%CI 16.2-NE) in Arm B (CT). Median OS was not reached in patients with SUV≥2. 60-month OS rate was 41.6% (95%CI 10.4-71.1%) in Arm A, 42.0% (95%CI 14.0-68.2%) in Arm B and 59.6% (95%CI 48.6-69.0%) in patients with SUV≥2. In patients with SUV≥2, 60-months OS rate was 72.6% if treated with aromatase inhibitors versus 40.6% in case of fulvestrant or tamoxifen (p<0.005). CONCLUSIONS The ET-FES trial demonstrated that ER+/HER2- MBC patients are a heterogeneous population, with different levels of endocrine responsiveness based on 18F-FES CT/PET SUV.
Collapse
Affiliation(s)
- A Gennari
- Department of Traslational Medicine, University of Piemonte Orientale, Novara, Italy;; Division of Medical Oncology, Maggiore University Hospital, Novara, Italy.
| | - E Brain
- Department of Medical Oncology, Institut Curie - Hôpital René Huguenin, Saint-Cloud, France
| | - A De Censi
- Medical Oncology, E.O. "Ospedali Galliera, Genova, Italy
| | - O Nanni
- Biostatistics and Clinical Trials Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - R Wuerstlein
- Department of Obstetrics and Gynecology and CCC Munich, LMU University Hospital, Munich, Germany
| | - A Frassoldati
- Clinical Oncology, S. Anna University Hospital, Ferrara, Italy
| | - J Cortes
- International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Barcelona, Spain; Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain
| | - V Rossi
- Division of Medical Oncology, Maggiore University Hospital, Novara, Italy
| | - M Palleschi
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - J L Alberini
- Nuclear Medicine Department Centre Georges-Francois Leclerc, Dijon Cedex, France
| | - F Matteucci
- Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo studio dei tumori (IRST)- Dino Amadori, Meldola, Italy
| | - A Piccardo
- Department of Nuclear Medicine, E.O. "Ospedali Galliera, Genova, Italy
| | - G Sacchetti
- Division of Nuclear Medicine Unit, Maggiore University Hospital, Novara, Italy
| | - H Ilhan
- Department of Nuclear Medicine, LMU University Hospital, Munich, Germany
| | - F D'Avanzo
- Division of Medical Oncology, Maggiore University Hospital, Novara, Italy
| | - B Ruffilli
- Department of Traslational Medicine, University of Piemonte Orientale, Novara, Italy
| | - S Nardin
- Medical Oncology Unit 1, IRCCS - Ospedale Policlinico San Martino, Genoa, Italy
| | - M Monti
- Biostatistics and Clinical Trials Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - M Puntoni
- Clinical and Epidemiological Research Unit, University Hospital of Parma, Parma, Italy
| | - V Fontana
- Department of Clinical Epidemiology, IRCSS Ospedale Policlinico San Martino, Genoa 20900, Italy
| | - L Boni
- Department of Clinical Epidemiology, IRCSS Ospedale Policlinico San Martino, Genoa 20900, Italy
| | - N Harbeck
- Department of Obstetrics and Gynecology and CCC Munich, LMU University Hospital, Munich, Germany
| |
Collapse
|
6
|
Meloni A, Pistoia L, Ricchi P, Maggio A, Cecinati V, Longo F, Sorrentino F, Borsellino Z, Salvo A, Rossi V, Grassedonio E, Restaino G, Renne S, Righi R, Positano V, Cademartiri F. Prognostic Role of Multiparametric Cardiac Magnetic Resonance in Neo Transfusion-Dependent Thalassemia. J Clin Med 2024; 13:1281. [PMID: 38592121 PMCID: PMC10931742 DOI: 10.3390/jcm13051281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Revised: 02/13/2024] [Accepted: 02/21/2024] [Indexed: 04/10/2024] Open
Abstract
BACKGROUND We prospectively evaluated the predictive value of multiparametric cardiac magnetic resonance (CMR) for cardiovascular complications in non-transfusion-dependent β-thalassemia (β-NTDT) patients who started regular transfusions in late childhood/adulthood (neo β-TDT). METHODS We considered 180 patients (38.25 ± 11.24 years; 106 females). CMR was used to quantify cardiac iron overload, biventricular function, and atrial dimensions, and to detect left ventricular (LV) replacement fibrosis. RESULTS During a mean follow-up of 76.87 ± 41.60 months, 18 (10.0%) cardiovascular events were recorded: 2 heart failures, 13 arrhythmias (10 supraventricular), and 3 cases of pulmonary hypertension. Right ventricular (RV) end-diastolic volume index (EDVI), RV mass index (MI), LV replacement fibrosis, and right atrial (RA) area index emerged as significant univariate prognosticators of cardiovascular complications. The low number of events prevented us from performing a multivariable analysis including all univariable predictors simultaneously. Firstly, a multivariable analysis including the two RV size parameters (mass and volume) was carried out, and only the RV MI was proven to independently predict cardiovascular diseases. Then, a multivariable analysis, including RV MI, RA atrial area, and LV replacement fibrosis, was conducted. In this model, RV MI and LV replacement fibrosis emerged as independent predictors of cardiovascular outcomes (RV MI: hazard ratio (HR) = 1.18; LV replacement fibrosis: HR = 6.26). CONCLUSIONS Our results highlight the importance of CMR in cardiovascular risk stratification.
Collapse
Affiliation(s)
- Antonella Meloni
- Bioengineering Unit, Fondazione G. Monasterio CNR-Regione Toscana, 56124 Pisa, Italy; (A.M.); (V.P.)
- Department of Radiology, Fondazione G. Monasterio CNR-Regione Toscana, 56124 Pisa, Italy;
| | - Laura Pistoia
- Department of Radiology, Fondazione G. Monasterio CNR-Regione Toscana, 56124 Pisa, Italy;
- Unità Operativa Complessa Ricerca Clinica, Fondazione G. Monasterio CNR-Regione Toscana, 56124 Pisa, Italy
| | - Paolo Ricchi
- Unità Operativa Semplice Dipartimentale Malattie Rare del Globulo Rosso, Azienda Ospedaliera di Rilievo Nazionale “A. Cardarelli”, 80131 Napoli, Italy;
| | - Aurelio Maggio
- Ematologia II con Talassemia, Ospedale “V. Cervello”, 90100 Palermo, Italy;
| | - Valerio Cecinati
- Struttura Semplice di Microcitemia, Ospedale “SS. Annunziata”, 74123 Taranto, Italy;
| | - Filomena Longo
- Unità Operativa Day Hospital della Talassemia e delle Emoglobinopatie, Azienda Ospedaliero-Universitaria “S. Anna”, 44124 Cona, FE, Italy;
| | - Francesco Sorrentino
- Unità Operativa Semplice Dipartimentale Day Hospital Talassemici, Ospedale “Sant’Eugenio”, 00143 Rome, Italy;
| | - Zelia Borsellino
- Unità Operativa Complessa Ematologia con Talassemia, ARNAS Civico “Benfratelli-Di Cristina”, 90134 Palermo, Italy;
| | - Alessandra Salvo
- Operativa Semplice Talassemia, Presidio Ospedaliero “Umberto I”, 96100 Siracusa, Italy;
| | - Vincenza Rossi
- Unità Operativa Complessa Ematologia, Ospedale di Cosenza, 87100 Cosenza, Italy;
| | - Emanuele Grassedonio
- Sezione di Scienze Radiologiche, Dipartimento di Biopatologia e Biotecnologie Mediche, Policlinico “Paolo Giaccone”, 90127 Palermo, Italy;
| | - Gennaro Restaino
- Unità Operativa Complessa Radiodiagnostica, Gemelli Molise SpA, Fondazione di Ricerca e Cura “Giovanni Paolo II”, 86100 Campobasso, Italy;
| | - Stefania Renne
- Struttura Complessa di Cardioradiologia-UTIC, Presidio Ospedaliero “Giovanni Paolo II”, 88046 Lamezia Terme, CZ, Italy;
| | - Riccardo Righi
- Diagnostica per Immagini e Radiologia Interventistica, Ospedale del Delta, 44023 Lagosanto, FE, Italy;
| | - Vincenzo Positano
- Bioengineering Unit, Fondazione G. Monasterio CNR-Regione Toscana, 56124 Pisa, Italy; (A.M.); (V.P.)
- Department of Radiology, Fondazione G. Monasterio CNR-Regione Toscana, 56124 Pisa, Italy;
| | - Filippo Cademartiri
- Department of Radiology, Fondazione G. Monasterio CNR-Regione Toscana, 56124 Pisa, Italy;
| |
Collapse
|
7
|
Calcaterra V, Gazzarri A, De Silvestri A, Madia C, Baldassarre P, Rossi V, Garella V, Zuccotti G. Thyroid function, sensitivity to thyroid hormones, and metabolic syndrome in euthyroid children and adolescents with Down syndrome. J Endocrinol Invest 2023; 46:2319-2325. [PMID: 37040064 DOI: 10.1007/s40618-023-02086-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Accepted: 03/30/2023] [Indexed: 04/12/2023]
Abstract
PURPOSE Patients with Down Syndrome (DS) showed multiple comorbidities, including thyroid disorders, obesity, and metabolic derangement. Different thyroid hormone (THs) patterns and sensitivity to thyroid hormone indices (STHI) seem to be associated with metabolic disorders. The study's aim was to evaluate the prevalence of metabolic syndrome (MS) in pediatric patients affected by DS, taking into consideration the relationship between the metabolic parameters, THs and STHI. METHODS We enlisted 50 euthyroid patients with DS (9.03 ± 4.46). Clinical parameters, TSH, FT3, FT4 and the presence of MS were recorded. Indexes of peripheral sensitivity (FT3/FT4 ratio) and central sensitivity (TSH index, TSHI; TSH T4 resistance index, TT4RI; TSH T3 resistance index, TT3RI) were also detected. Thirty healthy subjects were included as a control group. RESULTS MS was detected in 12% of the subjects with DS. FT3, FT4, and TSH levels were higher in DS than in the control group (p < 0.01); higher levels of FT3/FT4 ratio, TSHI and TT3RI and lower TT4RI values (p < 0.01) were also detected. A significant correlation was detected between FT3 and fasting blood glucose (FBG) (R = 0.46), triglyceride (TG) (r = 0.37), total (r = 0.55) and high density lipoprotein-cholesterol (HDL-C) (r = - 0.38), diastolic blood pressure (DBP) (r = - 0.4); FT3/FT4 ratio and waist circumference (WC) (r = 0.36); TSHI and total (r = 0.30) and HDL cholesterol (r = - 0.31); TT4RI and HDL cholesterol (r = - 0.31); TT3RI and total (r = 0.39) and HDL cholesterol (r = - 032). CONCLUSION We confirmed a higher MS prevalence in children with DS compared to the control group. A significant association between THs, STHI, and the glucose and lipid metabolism parameters was detected supporting their role in metabolic alterations related to the DS.
Collapse
Affiliation(s)
- V Calcaterra
- Pediatric and Adolescent Unit, Department of Internal Medicine, University of Pavia, 27100, Pavia, Italy.
- Pediatric Department, "V. Buzzi" Children's Hospital, 20154, Milan, Italy.
| | - A Gazzarri
- Associazione Vivi Down Onlus, 20158, Milan, Italy
| | - A De Silvestri
- Biometry & Clinical Epidemiology, Scientific Direction, Fondazione IRCCS Policlinico San Matteo, 27100, Pavia, Italy
| | - C Madia
- Associazione Vivi Down Onlus, 20158, Milan, Italy
| | - P Baldassarre
- Pediatric Department, "V. Buzzi" Children's Hospital, 20154, Milan, Italy
| | - V Rossi
- Pediatric Department, "V. Buzzi" Children's Hospital, 20154, Milan, Italy
| | - V Garella
- Pediatric Department, "V. Buzzi" Children's Hospital, 20154, Milan, Italy
| | - G Zuccotti
- Department of Biomedical and Clinical Science "L. Sacco", University of Milan, 20157, Milan, Italy
| |
Collapse
|
8
|
Martins Pinto Filho M, Paixao GMM, Soares CPM, Gomes PR, Raspail L, Rossi V, Singh K, Perel P, Prabhakaran D, Sliwa-Hahnle K, Ribeiro ALP. ECG abnormalities and their relation to COVID-19 outcomes – a WHF study. Eur Heart J 2022. [PMCID: PMC9619533 DOI: 10.1093/eurheartj/ehac544.390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Introduction COVID-19 is a respiratory tract infection caused by the Coronavirus (SARS-CoV-2) and its main clinical manifestations are respiratory. The cardiovascular system can also be affected, especially in patients with severe acute respiratory syndrome [1]. On the other hand, cardiovascular disease (CVD) and risk factors have been shown to be predictors of poor outcomes in COVID-19 [2]. Diverse electrocardiographic abnormalities can be found in this condition [3], although their value as a prognostic predictor have not been properly established due to heterogeneity in abnormalities evaluation and small sample sizes in related studies [4]. Purpose The aim of the present study is to evaluate the association of electrocardiogram (ECG) findings to poor COVID-19 outcomes Methods This is a multicentric cohort study that followed hospitalized adults due to COVID-19, from low-middle and high-income countries as part of the World Heart Federation (WHF) Global Study on CVD and COVID-19 initiative [5]. Participants were followed up from hospital admission until 30 days post discharge. For the present study, participants with a valid ECG were included. ECG findings were described according to standardized measurements [heart rate, PR interval, QRS duration and axis, corrected QT interval (QTc)] and abnormalities (according to the Minnesota code system). Abnormalities utilized were grouped into ischemic abnormalities (q waves and ST-T abnormalities), atrial fibrillation (AF), prolonged QTc, sinus tachycardia (defined for the study as above 120 bpm), right and left bundle branch block and presence of any major abnormality. The primary outcome was defined as death from any cause. The secondary outcomes were intensive care unit (ICU) admission and cardiovascular events (myocarditis, pericarditis, myocardial infarction, acute heart failure, ischemic and hemorrhagic stroke). Multiple logistic regression was used to evaluate the association of ECG abnormalities to the outcomes of interest. Adjustments were made in a step by step fashion including gender, age, country of residence, cardiovascular risk factors (diabetes, hypertension, tobacco use) and presence of comorbidities (CVD, asthma, cancer, immunosuppression and chronic kidney disease). Results The clinical characteristics of the cohort are described in table 1. Figure 1 represents the odds ratio and its 95% confidence interval of having the defined outcomes when presenting a ECG abnormality for the final regression model. Conclusion ECG abnormalities were independently related to poor outcomes in COVID-19 after accounting for multiple confounders. Significant associations were more frequently found for ischemic abnormalities, heart rate above 120 bpm, atrial fibrillation and having at least one major electrocardiographic abnormality. Funding Acknowledgement Type of funding sources: Other. Main funding source(s): Pfizer and Sanofi PasteurWorld Heart Federation
Collapse
Affiliation(s)
| | - G M M Paixao
- Federal University of Minas Gerais , Belo Horizonte , Brazil
| | - C P M Soares
- Federal University of Minas Gerais , Belo Horizonte , Brazil
| | - P R Gomes
- Federal University of Minas Gerais , Belo Horizonte , Brazil
| | - L Raspail
- World Heart Federation , Geneva , Switzerland
| | - V Rossi
- University Heart Center , Zurich , Switzerland
| | - K Singh
- Public Health Foundation of India , Gurugram , India
| | - P Perel
- London School of Hygiene and Tropical Medicine , London , United Kingdom
| | - D Prabhakaran
- Public Health Foundation of India , Gurugram , India
| | | | - A L P Ribeiro
- Federal University of Minas Gerais , Belo Horizonte , Brazil
| |
Collapse
|
9
|
D'Avanzo F, Rossi V, Saggia C, Platini F, Borra G, Martini V, Rua A, Gioffi E, Branni C, Maggiora P, Tassone A, Varughese F, Ram Vachanaram A, Ben Ayed R, Angelillo C, Barcellini A, Boldorini R, Dodaro I, Ferrante D, Gennari A. 159P Peripheral T-lymphocytes senescence and response to neoadjuvant therapy (NAT) in operable breast cancer (BC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
10
|
Gennari A, Brain E, Nanni O, Harbeck N, Cortés J, De Censi A, Piccardo A, Alberini J, Matteucci F, Sacchetti G, Ilhan H, Monti M, Wuerlestein R, Saggia C, Rossi V, D'Avanzo F, Maggiora P, Iacozzi M, Frassoldati A, Boni L. 221P Early prediction of efficacy of endocrine therapy (ET) in metastatic breast cancer (MBC): Pilot study with [18F]fluoro-estradiol-17β (18F-FES) PET/CT. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
11
|
Furiosi M, Hasanaliyeva G, Caffi T, Rossi V. Soil covering and biofumigant effect of Armoracia rusticana against spore dispersal and viability of Downy mildew inoculum in viticultural systems-BIOVINE. BIO Web Conf 2022. [DOI: 10.1051/bioconf/20225003004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Furiosi M, Rossi V, Legler S, Caffi T. Study on fungicides’ use in viticulture: present and future scenarios to control powdery and downy mildew. BIO Web Conf 2022. [DOI: 10.1051/bioconf/20225003006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Taibi O, Bardelloni V, Bove F, Scaglia F, Caffi T, Rossi V. Activity of resistance inducers against Plasmopara viticola in vineyard. BIO Web Conf 2022. [DOI: 10.1051/bioconf/20225003003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Salotti I, Bove F, Rossi V. Field evaluation of grapevines resistant to downy and powdery mildews. BIO Web Conf 2022. [DOI: 10.1051/bioconf/20225002003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
15
|
Taibi O, Furiosi M, Caffi T, Rossi V. Characterization of the Folpet fungicidal activity against Plasmopara viticola. BIO Web Conf 2022. [DOI: 10.1051/bioconf/20225003002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
van der Fels-Klerx H, Liu C, Focker M, Montero-Castro I, Rossi V, Manstretta V, Magan N, Krska R. Decision support system for integrated management of mycotoxins in feed and food supply chains. WORLD MYCOTOXIN J 2021. [DOI: 10.3920/wmj2020.2603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Mycotoxins present a global food safety threat of our feed and food. Mycotoxins are toxic metabolites of certain fungi in agricultural products that are harmful to animal and human health. The presence of mycotoxins in these products depends on a variety of management and environmental factors in the field, during storage and/or processing of feed and food commodities. To date, information on mycotoxin management is available, but is not easy to access by supply chain actors. This study aimed to design, build and test a Decision Support System (DSS) that can help decision making on mycotoxin management by various actors along the feed and food supply chains. As part of this, available knowledge and data on mycotoxin prevention and control were collected and synthesised into easy to understand guidelines and tools for various groups of end-users. The DSS consists of four different modules: (a) static information module and (b) scenario analysis module, (c) dynamic module for forecasting mycotoxins, and (d) dynamic module for real-time monitoring of moulds/mycotoxins in grain silos. Intended end-users are all end-user groups for modules (a) and (b); growers and collectors for module (c) and; post-harvest storage managers for module (d). The DSS is user-friendly and accessible through PCs, tablets and smartphones (see https://mytoolbox-platform.com/ ). In various phases of the DSS development, the tool has been demonstrated to groups of end-users, and their suggestions have been taken into account, whenever possible. Also, a near final version has been tested with individual farmers on the easiness to use the system. In this way we aimed to maximise the DSS uptake by actors along the chain. Ultimately, this DSS will improve decision making on mycotoxin management; it will assist in reducing mycotoxin contamination in the key crops of Europe, thereby reducing economic losses and improving animal and human health.
Collapse
Affiliation(s)
- H.J. van der Fels-Klerx
- Wageningen Food Safety Research, Akkermaalsbos 2, 6708 WB Wageningen, the Netherlands
- Wageningen University, Business Economics Group, Hollandseweg 1, 6706 KN, Wageningen, the Netherlands
| | - C. Liu
- Wageningen Food Safety Research, Akkermaalsbos 2, 6708 WB Wageningen, the Netherlands
| | - M. Focker
- Wageningen University, Business Economics Group, Hollandseweg 1, 6706 KN, Wageningen, the Netherlands
| | - I. Montero-Castro
- IRIS Technology Solutions S.L., Avda. Carl Friedrich Gauss 11, 08860 Castelldefels, Barcelona, Spain
| | - V. Rossi
- Università Cattolica del Sacro Cuore, via Emilia Parmense 84, 29122 Piacenza, Italy
| | - V. Manstretta
- Horta s.r.l., via Egidio Gorra 55, 29122 Piacenza, Italy
| | - N. Magan
- Applied Mycology Group, Environment and AgriFood Theme, Cranfield University, Cranfield, Beds. MK43 0AL, United Kingdom
| | - R. Krska
- Institute of Bioanalytics and Agro-Metabolomics, Department IFA-Tulln, University of Natural Resources and Life Sciences, Vienna (BOKU), Konrad-Lorenz-Str. 20, 3430 Tulln, Austria
- Institute for Global Food Security, School of Biological Sciences, Queens University Belfast, University Road, Belfast, BT7 1NN, Northern Ireland, United Kingdom
| |
Collapse
|
17
|
Griguolo G, Tosi A, Dieci M, Fineberg S, Ventura A, Bottosso M, Bauchet L, Miglietta F, Jacob J, Rossi V, Rigau V, Jacot W, Conte P, Rosato A, Darlix A, Guarneri V. 281P Prognostic impact of immune interactions in HER2+ and triple-negative breast cancer brain metastases. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
18
|
Del Castillo LM, Buigues A, Rossi V, Soriano MJ, Martinez J, De Felici M, Lamsira HK, Di Rella F, Klinger FG, Pellicer A, Herraiz S. The cyto-protective effects of LH on ovarian reserve and female fertility during exposure to gonadotoxic alkylating agents in an adult mouse model. Hum Reprod 2021; 36:2514-2528. [PMID: 34333622 PMCID: PMC8373474 DOI: 10.1093/humrep/deab165] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Revised: 05/07/2021] [Indexed: 12/15/2022] Open
Abstract
STUDY QUESTION Does LH protect mouse oocytes and female fertility from alkylating chemotherapy? SUMMARY ANSWER LH treatment before and during chemotherapy prevents detrimental effects on follicles and reproductive lifespan. WHAT IS KNOWN ALREADY Chemotherapies can damage the ovary, resulting in premature ovarian failure and reduced fertility in cancer survivors. LH was recently suggested to protect prepubertal mouse follicles from chemotoxic effects of cisplatin treatment. STUDY DESIGN, SIZE, DURATION This experimental study investigated LH effects on primordial follicles exposed to chemotherapy. Seven-week-old CD-1 female mice were randomly allocated to four experimental groups: Control (n = 13), chemotherapy (ChT, n = 15), ChT+LH-1x (n = 15), and ChT+LH-5x (n = 8). To induce primary ovarian insufficiency (POI), animals in the ChT and ChT+LH groups were intraperitoneally injected with 120 mg/kg of cyclophosphamide and 12 mg/kg of busulfan, while control mice received vehicle. For LH treatment, the ChT+LH-1x and ChT+LH-5x animals received a 1 or 5 IU LH dose, respectively, before chemotherapy, then a second LH injection administered with chemotherapy 24 h later. Then, two animals/group were euthanized at 12 and 24 h to investigate the early ovarian response to LH, while remaining mice were housed for 30 days to evaluate short- and long-term reproductive outcomes. The effects of LH and chemotherapy on growing-stage follicles were analyzed in a parallel experiment. Seven-week-old NOD-SCID female mice were allocated to control (n = 5), ChT (n = 5), and ChT+LH-1x (n = 6) groups. Animals were treated as described above, but maintained for 7 days before reproductive assessment. PARTICIPANTS/MATERIALS, SETTING, METHODS In the first experiment, follicular damage (phosphorylated H2AX histone (γH2AX) staining and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay), apoptotic biomarkers (western blot), and DNA repair pathways (western blot and RT-qPCR) were assessed in ovaries collected at 12 and 24 h to determine early ovarian responses to LH. Thirty days after treatments, remaining mice were stimulated (10 IU of pregnant mare serum gonadotropin (PMSG) and 10 IU of hCG) and mated to collect ovaries, oocytes, and embryos. Histological analysis was performed on ovarian samples to investigate follicular populations and stromal status, and meiotic spindle and chromosome alignment was measured in oocytes by confocal microscopy. Long-term effects were monitored by assessing pregnancy rate and litter size during six consecutive breeding attempts. In the second experiment, mice were stimulated and mated 7 days after treatments and ovaries, oocytes, and embryos were collected. Follicular numbers, follicular protection (DNA damage and apoptosis by H2AX staining and TUNEL assay, respectively), and ovarian stroma were assessed. Oocyte quality was determined by confocal analysis. MAIN RESULTS AND THE ROLE OF CHANCE LH treatment was sufficient to preserve ovarian reserve and follicular development, avoid atresia, and restore ovulation and meiotic spindle configuration in mature oocytes exposed at the primordial stage. LH improved the cumulative pregnancy rate and litter size in six consecutive breeding rounds, confirming the potential of LH treatment to preserve fertility. This protective effect appeared to be mediated by an enhanced early DNA repair response, via homologous recombination, and generation of anti-apoptotic signals in the ovary a few hours after injury with chemotherapy. This response ameliorated the chemotherapy-induced increase in DNA-damaged oocytes and apoptotic granulosa cells. LH treatment also protected growing follicles from chemotherapy. LH reversed the chemotherapy-induced depletion of primordial and primary follicular subpopulations, reduced oocyte DNA damage and granulosa cell apoptosis, restored mature oocyte cohort size, and improved meiotic spindle properties. LARGE SCALE DATA N/A. LIMITATIONS, REASONS FOR CAUTION This was a preliminary study performed with mouse ovarian samples. Therefore, preclinical research with human samples is required for validation. WIDER IMPLICATIONS OF THE FINDINGS The current study tested if LH could protect the adult mouse ovarian reserve and reproductive lifespan from alkylating chemotherapy. These findings highlight the therapeutic potential of LH as a complementary non-surgical strategy for preserving fertility in female cancer patients. STUDY FUNDING/COMPETING INTEREST(S) This study was supported by grants from the Regional Valencian Ministry of Education (PROMETEO/2018/137), the Spanish Ministry of Science and Innovation (CP19/00141), and the Spanish Ministry of Education, Culture and Sports (FPU16/05264). The authors declare no conflict of interest.
Collapse
Affiliation(s)
- L M Del Castillo
- IVI Foundation—IIS La Fe, Reproductive Medicine Research Group, Valencia, Spain
- Department of Pediatrics, Obstetrics and Gynecology, School of Medicine, University of Valencia, Valencia, Spain
| | - A Buigues
- IVI Foundation—IIS La Fe, Reproductive Medicine Research Group, Valencia, Spain
| | - V Rossi
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| | - M J Soriano
- IVI Foundation—IIS La Fe, Reproductive Medicine Research Group, Valencia, Spain
| | - J Martinez
- IVI Foundation—IIS La Fe, Reproductive Medicine Research Group, Valencia, Spain
- Department of Pediatrics, Obstetrics and Gynecology, School of Medicine, University of Valencia, Valencia, Spain
| | - M De Felici
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| | - H K Lamsira
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| | - F Di Rella
- Clinical and Experimental Senology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Naples, Italy
| | - F G Klinger
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| | - A Pellicer
- IVI Foundation—IIS La Fe, Reproductive Medicine Research Group, Valencia, Spain
- IVI-RMA Rome, Rome, Italy
| | - S Herraiz
- Correspondence address. IVI Foundation—IIS La Fe, Reproductive Medicine Research Group, Av. Fernando Abril Martorell, 106-Torre A-Planta1, 46026 Valencia, Spain. Tel: +34-96-390-33-05; E-mail: https://orcid.org/0000-0003-0703-6922
| |
Collapse
|
19
|
d'Arma A, Rossi V, Pugnetti L, Grosso C, Sinatra M, Dos Santos R, Di Giusto G, Mendozzi L. Managing chronic disease in the COVID-19 pandemic: an e-learning application to promote a healthy lifestyle for persons with multiple sclerosis. PSYCHOL HEALTH MED 2021; 27:428-435. [PMID: 34130565 DOI: 10.1080/13548506.2021.1939072] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
E-health applications can support continuing care for persons with chronic diseases such as multiple sclerosis (MS). We have developed a web-based mobile app called VIOLA to be used at home by persons with MS (pwMS) who previously participated in an innovative multidisciplinary rehab program. The purpose of VIOLA is to reinforce what participants have learned about a healthy lifestyle and to keep them motivated to adhere to rehabilitation programs. As the outbreak of the Covid-19 pandemic has severely curtailed pwMS contact with their usual health providers, we quickly updated VIOLA to grant continuity of care to our home-bound patients.By monitoring pwMS subscriptions to individual modules, we found a definite increase after the national lockdown was declared. Subscribers rated the app very positively.Encouraged by the positive feedbacks, we are planning to extend the access to our app also to pwMS with no prior specific learning experience. This would limit the psychophysical consequences of the lockdown. Furthermore, VIOLA could be effective in maintaining a proper lifestyle, contributing to improve the quality of life of pwMS.VIOLA has the potential of increasing the adherence of pwMS to the rehabilitation confirming that digital communication tools are a valuable solution for those home-bound.].
Collapse
Affiliation(s)
- A d'Arma
- IRCCS Fondazione Don Carlo Gnocchi, Unit of Neuromotor Rehabilitation, Multiple Sclerosis Center, Milan, Italy
| | - V Rossi
- IRCCS Fondazione Don Carlo Gnocchi, Unit of Neuromotor Rehabilitation, Multiple Sclerosis Center, Milan, Italy
| | - L Pugnetti
- IRCCS Fondazione Don Carlo Gnocchi, Unit of Neuromotor Rehabilitation, Multiple Sclerosis Center, Milan, Italy
| | - C Grosso
- IRCCS Fondazione Don Carlo Gnocchi, Unit of Neuromotor Rehabilitation, Multiple Sclerosis Center, Milan, Italy
| | - M Sinatra
- IRCCS Fondazione Don Carlo Gnocchi, Unit of Neuromotor Rehabilitation, Multiple Sclerosis Center, Milan, Italy
| | - R Dos Santos
- IRCCS Fondazione Don Carlo Gnocchi, Unit of Neuromotor Rehabilitation, Multiple Sclerosis Center, Milan, Italy
| | - G Di Giusto
- IRCCS Fondazione Don Carlo Gnocchi, Unit of Neuromotor Rehabilitation, Multiple Sclerosis Center, Milan, Italy.,Department of Biosciences, Università Degli Studi Di Milano, Milano, Italy
| | - L Mendozzi
- IRCCS Fondazione Don Carlo Gnocchi, Unit of Neuromotor Rehabilitation, Multiple Sclerosis Center, Milan, Italy
| |
Collapse
|
20
|
Spears N, Lopes F, Stefansdottir A, Rossi V, De Felici M, Anderson RA, Klinger FG. Ovarian damage from chemotherapy and current approaches to its protection. Hum Reprod Update 2020; 25:673-693. [PMID: 31600388 PMCID: PMC6847836 DOI: 10.1093/humupd/dmz027] [Citation(s) in RCA: 267] [Impact Index Per Article: 66.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2019] [Revised: 07/18/2019] [Accepted: 07/23/2019] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Anti-cancer therapy is often a cause of premature ovarian insufficiency and infertility since the ovarian follicle reserve is extremely sensitive to the effects of chemotherapy and radiotherapy. While oocyte, embryo and ovarian cortex cryopreservation can help some women with cancer-induced infertility achieve pregnancy, the development of effective methods to protect ovarian function during chemotherapy would be a significant advantage. OBJECTIVE AND RATIONALE This paper critically discusses the different damaging effects of the most common chemotherapeutic compounds on the ovary, in particular, the ovarian follicles and the molecular pathways that lead to that damage. The mechanisms through which fertility-protective agents might prevent chemotherapy drug-induced follicle loss are then reviewed. SEARCH METHODS Articles published in English were searched on PubMed up to March 2019 using the following terms: ovary, fertility preservation, chemotherapy, follicle death, adjuvant therapy, cyclophosphamide, cisplatin, doxorubicin. Inclusion and exclusion criteria were applied to the analysis of the protective agents. OUTCOMES Recent studies reveal how chemotherapeutic drugs can affect the different cellular components of the ovary, causing rapid depletion of the ovarian follicular reserve. The three most commonly used drugs, cyclophosphamide, cisplatin and doxorubicin, cause premature ovarian insufficiency by inducing death and/or accelerated activation of primordial follicles and increased atresia of growing follicles. They also cause an increase in damage to blood vessels and the stromal compartment and increment inflammation. In the past 20 years, many compounds have been investigated as potential protective agents to counteract these adverse effects. The interactions of recently described fertility-protective agents with these damage pathways are discussed. WIDER IMPLICATIONS Understanding the mechanisms underlying the action of chemotherapy compounds on the various components of the ovary is essential for the development of efficient and targeted pharmacological therapies that could protect and prolong female fertility. While there are increasing preclinical investigations of potential fertility preserving adjuvants, there remains a lack of approaches that are being developed and tested clinically.
Collapse
Affiliation(s)
- N Spears
- Biomedical Sciences, University of Edinburgh, Edinburgh UK
| | - F Lopes
- Biomedical Sciences, University of Edinburgh, Edinburgh UK
| | | | - V Rossi
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| | - M De Felici
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| | - R A Anderson
- MRC Centre for Reproductive Health, University of Edinburgh, Edinburgh UK
| | - F G Klinger
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| |
Collapse
|
21
|
Rossi V, Viozzi E, Tripodi F, Porpora M, Simonelli C, Nimbi F. Endometriosis, sexuality and satisfaction: A pilot study on women with and without infertility. Sexologies 2020. [DOI: 10.1016/j.sexol.2020.01.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
22
|
Legrand T, Di Franco A, Ser-Giacomi E, Caló A, Rossi V. A multidisciplinary analytical framework to delineate spawning areas and quantify larval dispersal in coastal fish. Mar Environ Res 2019; 151:104761. [PMID: 31399203 DOI: 10.1016/j.marenvres.2019.104761] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/05/2019] [Revised: 06/12/2019] [Accepted: 07/15/2019] [Indexed: 06/10/2023]
Abstract
Assessing larval dispersal is essential to understand the structure and dynamics of marine populations. However, knowledge about early-life dispersal is sparse, and so is our understanding of the spawning process, perhaps the most obscure component of biphasic life cycles. Indeed, poorly known species-specific spawning modality and species-specific early-life traits, as well as the high spatio-temporal variability of the oceanic circulation experienced during larval drift, hamper our ability to appraise the realized connectivity of coastal fishes. Here, we propose an analytical framework which combines Lagrangian modelling, network theory, otolith analyses and biogeographical information to pinpoint and characterize larval sources which are then grouped into discrete spawning areas. Such well-delineated larval sources allow improving the quantitative evaluations of both dispersal scales and connectivity patterns. To illustrate its added value, our approach is applied to two case-studies focusing on Diplodus sargus and Diplodus vulgaris in the Adriatic sea. We evidence robust correlations between otolith geochemistry and modelled spawning areas to assess their relative importance for the larval replenishment of the Apulian coast. Our results show that, contrary to D. sargus, D. vulgaris larvae originate from both eastern and western Adriatic shorelines. Our findings also suggest that dispersal distances and dispersal surfaces scale differently with the pelagic larval duration. Furthermore, 30.8% of D. sargus larvae and 23.6% of D. vulgaris larvae of the Apulian populations originate from Marine protected area (MPA), exemplifying larval export from MPAs to surrounding unprotected areas. This flexible multidisciplinary framework, which can be adjusted to any coastal fish and oceanic system, exploits the explanatory power of a dispersal model, fine-tuned and backed-up by observations, to provide more reliable scientific basis for the management and conservation of marine ecosystems.
Collapse
Affiliation(s)
- T Legrand
- Mediterranean Institute of Oceanography (UM 110, UMR 7294), CNRS, Aix Marseille Univ., Univ. Toulon, IRD, 13288, Marseille, France.
| | - A Di Franco
- Stazione zoologica Anton Dohrn, Dipartimento Ecologia Marina Integrata, Sede Interdipartimentale della Sicilia, Lungomare Cristoforo Colombo (complesso Roosevelt), 90142 Palermo, Italy; Université Côte d'Azur, CNRS, UMR 7035 ECOSEAS, Parc Valrose 28, Avenue Valrose, 06108, Nice, France
| | - E Ser-Giacomi
- Sorbonne Universités (UPMC, Université Paris 06)-CNRS-IRD-MNHN, LOCEAN, 4 Place JUSSIEU, F-75005, PARIS, France
| | - A Caló
- Université Côte d'Azur, CNRS, UMR 7035 ECOSEAS, Parc Valrose 28, Avenue Valrose, 06108, Nice, France; Dipartimento di Scienze della Terra e del Mare (DiSTeM), Università di Palermo, Via Archirafi 20, 90123 Palermo, Italy
| | - V Rossi
- Mediterranean Institute of Oceanography (UM 110, UMR 7294), CNRS, Aix Marseille Univ., Univ. Toulon, IRD, 13288, Marseille, France
| |
Collapse
|
23
|
Briot C, Faure P, Parmentier AL, Nachury M, Trang C, Viennot S, Altwegg R, Bulois P, Thomassin L, Serrero M, Ah-Soune P, Gilletta C, Plastaras L, Simon M, Dray X, Caillo L, Del Tedesco E, Abitbol V, Zallot C, Degand T, Rossi V, Bonnaud G, Colin D, Morel B, Winkfield B, Danset JB, Filippi J, Amiot A, Attar A, Levy J, Peyrin-Biroulet L, Vuitton L. Efficacy, Tolerability, and Safety of Low-Volume Bowel Preparations for Patients with Inflammatory Bowel Diseases: The French Multicentre CLEAN Study. J Crohns Colitis 2019; 13:1121-1130. [PMID: 30785181 DOI: 10.1093/ecco-jcc/jjz040] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
BACKGROUND Standard high-volume polyethylene glycol [PEG] bowel preparations [PEG-4L] are recommended for patients with inflammatory bowel disease [IBD] undergoing colonoscopy. However, low-volume preparations [≤2 L of active volume] are often used in clinical practice. The aim of this study was to evaluate the efficacy, tolerability, and safety of the various bowel preparations for patients with IBD, including low-volume preparations. METHODS We conducted a French prospective multicentre observational study over a period of 1 month. Patients aged 18-75 years with IBD with an indication of colonoscopy independent of the study were enrolled. The choice of the preparation was left to the investigators, as per their usual protocol. The patients' characteristics, disease, and colonoscopy characteristics were recorded, and they were given self-reported questionnaires. RESULTS Twenty-five public and private hospitals enrolled 278 patients. Among them, 46 had a disease flare and 41 had bowel stenoses. Bowel preparations for colonoscopy were as follows: 42% received PEG-2L, 29% received sodium picosulfate [Pico], 15% received PEG-4L, and 14% had other preparations. The preparation did not reach the Boston's score efficacy outcome in the PEG-4L group in 51.2% of the patients [p = 0.0011]. The preparation intake was complete for 59.5% in the PEG-4L group, compared with 82.9% in the PEG-2L group and 93.8% in the Pico group [p < 0.0001]. Tolerability, as assessed by the patients' VAS, was significantly better for both Pico and PEG-2L compared with PEG-4L, and better for Pico compared with PEG-2L [p = 0.008; p = 0.0003]. In multivariate analyses, low-volume preparations were independent factors of efficacy and tolerability. Adverse events occurred in 4.3% of the patients. CONCLUSIONS Preparations with PEG-2L and Pico were equally safe, with better efficacy and tolerability outcomes compared with PEG-4L preparations. The best efficacy/tolerance/safety profile was achieved with the Pico preparation.
Collapse
Affiliation(s)
- C Briot
- Department of Gastroenterology, University Hospital of Besançon, University Bourgogne Franche-Comté, Besançon, France
| | - P Faure
- Department of Gastroenterology, Clinique Pasteur, Toulouse, France
| | - A L Parmentier
- Centre de Méthodologie Clinique, University Hospital of Besançon, Besançon, France
| | - M Nachury
- Gastroenterology Department, University Hospital of Lille, Lille, France
| | - C Trang
- Department of Hepatology and Gastroenterology, University Hospital Hotel Dieu, Nantes, France
| | - S Viennot
- Gastroenterology Department, University Hospital of Caen, Caen, France
| | - R Altwegg
- Department of Hepatology and Gastroenterology, University Hospital of St Eloi, Montpellier, France
| | - P Bulois
- Department of Gastroenterology, Hôpital Privé la Louvière, Ramsay Générale de Santé, Lille, France
| | - L Thomassin
- Department of Gastroenterology, University Hospital Charles Nicolle, Rouen, France
| | - M Serrero
- Department of Gastroenterology, APHM, Hopital Nord, Marseille, France
| | - P Ah-Soune
- Department of Hepatology and Gastroenterology, Toulon - La Seyne-sur-Mer Hospital, Toulon, France
| | - C Gilletta
- Department of Gastroenterology, University Hospital Rangueuil, Toulouse, France
| | - L Plastaras
- Department of Hepato-Gastroenterology, Hospital Pasteur, Colmar, France
| | - M Simon
- Gastroenterology Department, Institut Mutualiste Montsouris, Paris, France
| | - X Dray
- Department of Gastroenterology, Sorbonne University & APHP, Hôpital Saint-Antoine, Paris, France
| | - L Caillo
- Department of Gastroenterology and Hepatology, University Hospital Caremeau, Nimes, France
| | - E Del Tedesco
- Department of Gastroenterology, University Hospital of Saint-Etienne, Saint Priest en Jarez, France
| | - V Abitbol
- Department of Gastroenterology, University Hospital Cochin, Paris, France
| | - C Zallot
- Department of Gastroenterology, Inserm U954, University Hospital of Nancy, Lorraine University, Nancy, France
| | - T Degand
- Department of Gastroenterology, University Hospital Le Bocage, Dijon, France
| | - V Rossi
- Department of Gastroenterology, Hospital Haut Anjou, Château Gontier, France
| | - G Bonnaud
- Clinique Ambroise Paré, Toulouse, France
| | - D Colin
- Department of Gastroenterology, Clinique de la Miotte, Belfort, France
| | - B Morel
- Department of Gastroenterology, Centre Hospitalier de Villefranche-sur-Saône, Gleizé, France
| | - B Winkfield
- Department of Hepatology and Gastroenterology, Hôpital Nord Franche-Comté, Trevenans, France
| | - J B Danset
- Department of HepatoGastroenterology, European Georges-Pompidou Hospital, APHP, Paris, France
| | - J Filippi
- Department of Gastroenterology, University Hospital L'Archet, Nice, France
| | - A Amiot
- Department of Gastroenterology, Henri Mondor Hospital, APHP, Creteil, France
| | - A Attar
- Gastroenterology Department, Beaujon University Hospital, Clichy, France
| | - J Levy
- Department of Gastroenterology, Clinique des Cèdres, Cornebarrieu, France
| | - L Peyrin-Biroulet
- Department of Gastroenterology, Inserm U954, University Hospital of Nancy, Lorraine University, Nancy, France
| | - L Vuitton
- Department of Gastroenterology, University Hospital of Besançon, University Bourgogne Franche-Comté, Besançon, France
| | | |
Collapse
|
24
|
Cicardo G, Ursi P, Rossi V, Ceccarelli G, Di Matteo FM, Panarese A, D'Andrea V. The ERAS Protocol is at the forefront of the peri-operative pathway in colorectal surgery: monocentric clinical study. G Chir 2019; 40:276-289. [PMID: 32011978] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
INTRODUCTION Colon cancer is one of the most common neoplastic diseases, with onset in old age; the benefits of the ERAS protocol were evaluated in the peri-operative treatment of patients affected by this neoplasm. METHODS We studied 90 cases of colorectal neoplasia observed at the General Surgery UOC of the San Camillo de Lellis Hospital between September 2014 and April 2016, undergoing laparoscopic surgery and to which the ERAS protocol was applied; key points were the preoperative oral feeding, the epidural anesthesia, the reduced or failed hydro-electrolytic overload, the early mobilization and recovery of the feeding, the non-use of drainage. The most important parameers considered were the reduced duration of the operating hospital stay, the lower occurrence of early and distant complications. RESULTS 85 surgical procedures were performed with laparoscopic technique (94.4%) and 5 with traditional open technique (5.6%). The conversion rate was 5.8% (5/85). 29 surgical procedures of right hemicolectomy (32.2%) and 26 of anterior resection of the rectum (28.9%) were performed; in another 29 patients (32.2%) an intervention with an open traditional technique was performed. A balanced anesthesia was performed in 41 patients (45.6%); epidural anesthesia in 32 cases (35.6%); the Tap Block in 17 subjects (18.9%). The average volume of liquid infusion was 1664cc ± 714; the average post-operative hospital stay of 4.3 ± 0.9 days. CONCLUSIONS The ERAS protocol reduces the duration of the post-operative hospitalization, involves a lower incidence of precocious and remote complications, in particular if associated with a minimally invasive surgical method; it is easily applicable and reproducible in a hospital environment, with a marked reduction in healthcare management costs.
Collapse
|
25
|
Rossi V, Nimbi F, Aversa F, Tripodi F, Porpora M, Simonelli C. PS-02-005 Endometriosis and sexual functioning: How much do psycho-emotional factors matter? J Sex Med 2019. [DOI: 10.1016/j.jsxm.2019.03.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
26
|
D’Avanzo F, Saggia C, Rossi V, Siffredi G, Barone Adesi F, Gennari A. CDK 4/6 inhibitors plus endocrine therapy in ER positive metastatic breast cancer (MBC): Systematic review and meta-analysis of randomized clinical trials. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz100.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Rossi V, Giannarelli D, Berchialla P, Montemurro F, Ferretti G, Nistico' C, Vigna L, Cognetti F, Fabi A. Abstract P2-08-34: The network metanalysis of data from PALOMA 2, MONALEESA 2, MONARCH 3, FALCON, SWOG and FACT trials: Progression free survival (PFS) benefit from first-line endocrine-based therapies in postmenopausal women with HR+ HER2- metastatic breast cancer (MBC) according to different prognostic subgroups. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-08-34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
The three classes of Cycline Dependend Kinase (CDK) 4/6 inhibitors, Palbociclib (P), Ribociclib (R) and Abemaciclib (A), in combination with non-Steroidal Aromatase Inhibitors (nSAIs) showed improvement on Progression Free Survival (PFS) in patients with HR+/HER2- MBC compared to AIs monotherapy.
Fulvestrant (F) also showed a PFS benefit over AIs in first-line setting of endocrine naive patients (pts) which was even greater in pts whithout visceral disease.
The absence of direct comparison between F and CDK 4/6 combination therapies and their less favorable toxicity profile generated great interest in the identification of a specific subgroup of pts based on clinical and pathological factors for decision-making in the use of endocrine monotherapy.
This analysis combines data from six randomized phase III trials investigating the role of endocrine-based therapies in the first-line setting of HR+/HER2- MBC to identify clinical factors in the choice among available drugs.
Methods
A Bayesian network meta-analysis was carried out for PFS; Hazard Ratio (HR) and 95% CI were reported. Potential treatment effect modifying covariates were investigated using sub-group analysis, stratifying by age, ECOG, ethnicity, prior chemotherapy or endocrine therapy exposure, measurable disease at the time of metastasis occurrence, visceral or bone only disease, time from the initial diagnosis of breast cancer to the metastasis onset. Data analysis was performed using R Statistical Software version 3.5.0
Results
In the absence of direct comparison between CDK 4/6 inhibitors + nAIs and F endocrine-based therapies, all these therapeutic options resulted in significant PFS benefit compared to nAIs monotherapy (HR: 0.74; 95% CI 0.67-0.80). However, among the three classes of CDK 4/6 inhibitors and F a significant longer PFS was observed according to some clinical-pathological factors as followed reported: from P + nAIs in “bone only” disease (HR 0.47; CI 0.25-0.86); from A + nAis in “de novo” subgroup (HR 0.60; CI 0.37-0.97), in “Asian” population (HR 0.37; CI 0.16-0.85) and “non visceral” disease (HR 0.48 CI 0.25-0.89); from R + nAIs in “de novo” subgroup (HR 0.55; CI 0.32-0.95) and in “visceral” disease (HR 0.66 CI 0.45-0.96); from all the three combination strategies (A, P and R) in “prior endocrine” exposure subgroup (HR 0.47 CI 0.25-0.87; HR 0.60 CI 0.45-0.80; HR 0.64 CI 0.41-1.0, respectively). Even though no significant PFS benefit was observed in the remaining subgroups, combined CDK 4/6 strategies appeared more effective than F according to relative HR.
Conclusions
CDK 4/6 inhibitors endocrine-based therapies as first-line treatment for postmenopausal women with HR+/HER2- MBC showed PFS improvement, regardless of prognostic subgroup and additionally advantage was emerged by indirect comparison with F. Further direct comparative studies are needed to explore greater benefits from different therapeutic options.
Citation Format: Rossi V, Giannarelli D, Berchialla P, Montemurro F, Ferretti G, Nistico' C, Vigna L, Cognetti F, Fabi A. The network metanalysis of data from PALOMA 2, MONALEESA 2, MONARCH 3, FALCON, SWOG and FACT trials: Progression free survival (PFS) benefit from first-line endocrine-based therapies in postmenopausal women with HR+ HER2- metastatic breast cancer (MBC) according to different prognostic subgroups [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-08-34.
Collapse
Affiliation(s)
- V Rossi
- Breast Tumour Unit, S.Camillo-Forlanini Hospital of Rome, Rome, Italy; Istituto Regina Elena of Rome, Rome, Italy; University of Turin, Turin, Italy; Investigative Clinical Oncology (INCO)-Fondazione del Piemonte per l'Oncologia, Candiolo, Turin, Italy
| | - D Giannarelli
- Breast Tumour Unit, S.Camillo-Forlanini Hospital of Rome, Rome, Italy; Istituto Regina Elena of Rome, Rome, Italy; University of Turin, Turin, Italy; Investigative Clinical Oncology (INCO)-Fondazione del Piemonte per l'Oncologia, Candiolo, Turin, Italy
| | - P Berchialla
- Breast Tumour Unit, S.Camillo-Forlanini Hospital of Rome, Rome, Italy; Istituto Regina Elena of Rome, Rome, Italy; University of Turin, Turin, Italy; Investigative Clinical Oncology (INCO)-Fondazione del Piemonte per l'Oncologia, Candiolo, Turin, Italy
| | - F Montemurro
- Breast Tumour Unit, S.Camillo-Forlanini Hospital of Rome, Rome, Italy; Istituto Regina Elena of Rome, Rome, Italy; University of Turin, Turin, Italy; Investigative Clinical Oncology (INCO)-Fondazione del Piemonte per l'Oncologia, Candiolo, Turin, Italy
| | - G Ferretti
- Breast Tumour Unit, S.Camillo-Forlanini Hospital of Rome, Rome, Italy; Istituto Regina Elena of Rome, Rome, Italy; University of Turin, Turin, Italy; Investigative Clinical Oncology (INCO)-Fondazione del Piemonte per l'Oncologia, Candiolo, Turin, Italy
| | - C Nistico'
- Breast Tumour Unit, S.Camillo-Forlanini Hospital of Rome, Rome, Italy; Istituto Regina Elena of Rome, Rome, Italy; University of Turin, Turin, Italy; Investigative Clinical Oncology (INCO)-Fondazione del Piemonte per l'Oncologia, Candiolo, Turin, Italy
| | - L Vigna
- Breast Tumour Unit, S.Camillo-Forlanini Hospital of Rome, Rome, Italy; Istituto Regina Elena of Rome, Rome, Italy; University of Turin, Turin, Italy; Investigative Clinical Oncology (INCO)-Fondazione del Piemonte per l'Oncologia, Candiolo, Turin, Italy
| | - F Cognetti
- Breast Tumour Unit, S.Camillo-Forlanini Hospital of Rome, Rome, Italy; Istituto Regina Elena of Rome, Rome, Italy; University of Turin, Turin, Italy; Investigative Clinical Oncology (INCO)-Fondazione del Piemonte per l'Oncologia, Candiolo, Turin, Italy
| | - A Fabi
- Breast Tumour Unit, S.Camillo-Forlanini Hospital of Rome, Rome, Italy; Istituto Regina Elena of Rome, Rome, Italy; University of Turin, Turin, Italy; Investigative Clinical Oncology (INCO)-Fondazione del Piemonte per l'Oncologia, Candiolo, Turin, Italy
| |
Collapse
|
28
|
Fabi A, Giannarelli D, Botticelli A, Scagnoli S, Pellegrino A, Fabbri A, Corsi D, Magri V, Pizzuti L, Paris I, Bruni V, Pace R, Lanzetta G, Stani S, Moscetti L, Marchetti P, Piesco G, Cognetti F, Rossi V. Abstract P4-13-07: SEQUERPLUS: A multicenter real practice observational study investigating the endocrine-based (E) therapies sequential approach in hormonal receptor positive (HR+) HER2 negative (-) metastatic breast cancer (MBC). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-13-07] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Despite the sequential E therapy is recognized as the preferred approach for HR+/HER2- MBC, no data from clinical trials support the choice between the different sequential strategies.
Methods: In this retrospective study descriptive statistics are reported using the median (Interquartile range, IQR) or frequency. Progression Free Survival (PFS) curves were estimated with the Kaplan-Meier method and compared with the log-rank test. Analysis were performed by SPSS version 21.0 (SPSS Inc., Chicago, IL).
Results: From January 2006 to December 2017, 240 patients (pts) with HR+/HER2- MBC receiving at least two consecutive E therapies as first approach were selected from 12 italian cancer centers. The median age at the time of metastasis onset was 63.5 (IQR: 55-72.5) years; 184 (76.7%) pts were in menopausal status; 38 (16%) had de novo stage IV disease and the remaining 202 (84%) had recurrent BC with a median time of 78 months (5-396 months). At the beginning of MBC diagnosis, 148 (62%) pts had a single site of distant disease, 108 (45%) of whom had bone only disease and 45 (18.8%) presented visceral involvement too. The aromatase inhibitor (AI) was chosen as I-line therapy in 146 (60.9%) pts, followed by Fulvestrant (F) in 62 (25.8%) pts; the alternative I-line options were everolimus-exemestane (Eve-Exe), tamoxifene (T), Palbociclib (P)+AI and F+AI in 13 (5.4%), 14 (5.8%), 1 (0.4%) and 4 (1.7%) pts, respectively. The most favourite II-line option resulted F for 111 (46.2%) pts while the Eve-Exe combination was chosen in 70 (29.2%) pts, AI in 30 (12.5%) pts; T, AI+F, P+F and antiprogestincwere administered in 4 (1.7%), 4 (1.7%), 19 (7.9%) and 2 (0.8%) pts, respectively. For I and II-line, the AI followed by F (40%) and F followed by Eve-Exe (18%) were the most common sequential therapeutic approaches; the several alternative options were scanty used (in less than 10%). The median Progression-Free Survival (PFS) from first and second-line E therapies resulted 15.7 (95% CI 13.3-18.1) and 10.3 months (95% CI 8.7-11.9), respectively. Among 194 pts with disease progression after second-line E therapy, 87 (44.8%) received further E therapies with a median PFS 9.4 months (95% CI 7.9-10.9). The remaining 70 (29.2%) pts was treated with palliative chemotherapy. Interestingly, the median Overall Survival (OS) was even longer for pts receiving more lines of E therapies compared to the group with earlier introduction of chemotherapy (204.3 vs 92.8; p=0.007).
Finally, in the subgroup analyses a longer PFS benefit was observed in pts with disease recurrence over 12 months from initial diagnosis (38.1 vs 30.3 months p=0.04) and limited sites of disease involvement at the time of MBC diagnosis (37.6 vs 28.3 months, p=0.03)
Conclusions: The sequential use in first and second-line setting of E therapies for HR+/HER2- MBC improves median PFS up to 32.3 months. According to real practice experience the optimal sequences could be AIs followed by F and F followed by Eve-Exe. A role for these compounds should be redefined in the light of recently introduction of CDK 4/6 inhibitors in combination with AIs or F for the first or later lines.
Citation Format: Fabi A, Giannarelli D, Botticelli A, Scagnoli S, Pellegrino A, Fabbri A, Corsi D, Magri V, Pizzuti L, Paris I, Bruni V, Pace R, Lanzetta G, Stani S, Moscetti L, Marchetti P, Piesco G, Cognetti F, Rossi V. SEQUERPLUS: A multicenter real practice observational study investigating the endocrine-based (E) therapies sequential approach in hormonal receptor positive (HR+) HER2 negative (-) metastatic breast cancer (MBC) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-13-07.
Collapse
Affiliation(s)
- A Fabi
- Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
| | - D Giannarelli
- Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
| | - A Botticelli
- Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
| | - S Scagnoli
- Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
| | - A Pellegrino
- Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
| | - A Fabbri
- Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
| | - D Corsi
- Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
| | - V Magri
- Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
| | - L Pizzuti
- Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
| | - I Paris
- Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
| | - V Bruni
- Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
| | - R Pace
- Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
| | - G Lanzetta
- Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
| | - S Stani
- Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
| | - L Moscetti
- Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
| | - P Marchetti
- Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
| | - G Piesco
- Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
| | - F Cognetti
- Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
| | - V Rossi
- Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
| |
Collapse
|
29
|
Rossi V, Giannarelli D, Berchialla P, Nisticò C, Ferretti G, Gasparro S, Malaguti P, Russillo M, Catania G, Vigna L, Mancusi R, Cognetti F, Fabi A. Progression free survival (PFS) benefit from first line endocrine based therapies in postmenopausal women with HR+ HER2- metastatic breast cancer (MBC) according to different prognostic subgroups: A combined analysis of data from PALOMA 2, MONALEESA 2, MONARCH 3, FALCON, SWOG and FACT trials. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Rossi V, Tripodi F, Nimbi F, Simonelli C, Porpora M. 699 Genito-pelvic pain disorders and psychological functioning: a comparative study between patients with vulvodynia and endometriosis. J Sex Med 2018. [DOI: 10.1016/j.jsxm.2018.04.607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
31
|
Aversa F, Todaro E, Silvaggi M, Rossi V, Nimbi F, Rossi R, Tripodi F, Simonelli C. 638 May social media be a tool in promoting sexual health? Youth’s use, professional’s attitudes and current sexual education programs. J Sex Med 2018. [DOI: 10.1016/j.jsxm.2018.04.545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
32
|
Stasi R, Tribalto M, Venditti A, del Poeta G, Aronica G, Zaccar G, Rossi V, Maffei L, Papa G. Simultaneous Occurrence of Monoclonal Gammopathy and Acute Secondary Leukemia with Overexpression of P-Glycoprotein. Tumori 2018; 78:403-6. [PMID: 1363621 DOI: 10.1177/030089169207800613] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
A 52-year-old woman, previously treated with chemo- and radiotherapy for Hodgkin's disease, developed an acute non-lymphoid leukemia and, contemporarily, an IgG-kappa paraproteinemia. Cytogenetic analysis showed a major clone, representing 90% of observed metaphases, with monosomy of chromosomes 5 and 14. In addition, leukemic cells exhibited a high expression of the P-glycoprotein, a transmembrane glycoprotein involved in the multidrug-resistance mechanism. Possible explanations for this cluster of findings are provided.
Collapse
Affiliation(s)
- R Stasi
- Division of Hematology, II University of Rome Tor Vergata, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Callegaro L, Assone F, Cecconato E, Malinverni A, Pasteris V, Rossi V. Hollow Fiber Immobilized L-asparaginase: In Vivo and in Vitro Immunological Studies. Int J Artif Organs 2018. [DOI: 10.1177/039139888300600211] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The enzyme L-asparaginase was covalently immobilized on the inner surface of the hollow fibers utilized in a commercially available dialyzer by the periodate method. After sterilization with gamma radiation the bioreactor was able to metabolize in vivo, 90 per cent of circulating asparagine in two hours. The absence in blood of asparaginase-related protein fragments, released from the hollow fiber immobilized enzyme, was monitored using a specific enzyme-linked immunosorbent assay (ELISA).
Collapse
Affiliation(s)
- L. Callegaro
- Immunochemistry Research Laboratories, Sorin Biomedica S.p.A., Saluggia (Vercelli) - Italy
| | - F. Assone
- Immunochemistry Research Laboratories, Sorin Biomedica S.p.A., Saluggia (Vercelli) - Italy
| | - E. Cecconato
- Immunochemistry Research Laboratories, Sorin Biomedica S.p.A., Saluggia (Vercelli) - Italy
| | - A. Malinverni
- Immunochemistry Research Laboratories, Sorin Biomedica S.p.A., Saluggia (Vercelli) - Italy
| | - V. Pasteris
- Immunochemistry Research Laboratories, Sorin Biomedica S.p.A., Saluggia (Vercelli) - Italy
| | - V. Rossi
- Immunochemistry Research Laboratories, Sorin Biomedica S.p.A., Saluggia (Vercelli) - Italy
| |
Collapse
|
34
|
Abstract
The enzyme arginase, purified from bovine liver, was covalently immobilized by the glutaraldehyde method to the inner surface of Cuprophan hollow fibers of a conventional hemodialyzer with a surface 1.3 m3. The yield of the process was 0.3 μg/cm2 of active enzyme at physiological pH. The immobilization method did not adversely affect the physical and mechanical properties of hollow fibers neither their hemocompatibility. After sterilization with ethylene oxide, the bioreactor was able to metabolize five liters of 50 μM arginine solution at pH 7.4, in six hours.
Collapse
Affiliation(s)
- V. Rossi
- Laboratory of Enzymology Sorin Biomedica S.p.A. 13040 Saluggia, Vercelli, Italy
| | - A. Malinverni
- Laboratory of Enzymology Sorin Biomedica S.p.A. 13040 Saluggia, Vercelli, Italy
| | - L. Callegaro
- Laboratory of Enzymology Sorin Biomedica S.p.A. 13040 Saluggia, Vercelli, Italy
| |
Collapse
|
35
|
Marchiori A, Noto A, Rossi V, Daniele F, Santoro C, Ricchio R, De Lorenzo R, Umbaca R, Prandoni P, Bova C. Incidence of arterial cardiovascular events in patients with idiopathic venous thromboembolism. Thromb Haemost 2017. [DOI: 10.1160/th06-05-0231] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
SummaryRecent data have showna higher incidence of arterial events in patients with venous thromboembolism (VTE) of unknown origin than in those with the secondary form of disease. Whether patients with idiopathic VTE have a higher risk of subsequent arterial events than the general population is unknown. The aim was to evaluate the rates of subsequent arterial events in patients with idiopathic VTE and control subjects. In a retrospective cohort study we compared the rates of subsequent arterial events (i.e. acute myocardial infarction, ischemic stroke and peripheral arterial disease) in 151 consecutive patients with objectively confirmed spontaneousVTE and 151 control subjects randomly selected from the database of two family physicians. We collected information about cardiovascular risk-factors (hypertension, hypercholesterolemia, diabetes, obesity and smoke) at the time of VTE episode, or corresponding date for the controls, and considered the follow-up from this time. Patients and controls who had suffered from arterial events before the index date were excluded. During a mean follow-up of 43.1 (± 21.7) months there were 16 arterial events in theVTE patients and six in the control group (HR, 2.84; 95% CI, 1.11 to 7.27; p= 0.03).The difference remained significant after adjusting for age and other cardiovascular risk factors (HR 2.86; 95% CI, 1.07 to 7.62).Overall mortality was also higher in theVTE patients (12 vs.4 deaths). In conclusion, arterial events are more common in patients with previous idiopathic VTE than in the general population. These findings may have practical implications.
Collapse
|
36
|
Piredda M, Gambale G, Candela M, Mecugni D, Rasero L, Iacorossi L, Rossi V, Brice J, Capuzzo M, Migliore S, Petitti T, Pettinari E, Barbetta R, Fanni C, Marcucci M, Marchetti A, De Marinis M. Development and psychometric testing of a measure of perception of care dependency in cancer patients. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx438.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Tavella K, Villanucci A, Vannini L, Rossi V, Fantechi B, Capone G, Putignano A, Gensini F, Porfirio B, Amunni G, Mazzei T, Mini E, Papi L. Retrospective analysis of 77 patients with ovarian cancer undergoing genetic testing for BRCA1 and BRCA2 mutations. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx429.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Christine G, Kapferer-Seebacher I, Stoiber H, Bally I, Amberger A, Rossi V, Thielens N, Byers P, Zschocke J. Pathogenic mutations in C1R and C1S: In quest for molecular mechanisms. Mol Immunol 2017. [DOI: 10.1016/j.molimm.2017.06.185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
39
|
Montava M, Rossi V, CurtoFais CL, Mancini J, Lavieille JP. Long-term surgical results in microvascular decompression for hemifacial spasm: efficacy, morbidity and quality of life. Acta Otorhinolaryngol Ital 2017; 36:220-7. [PMID: 27214834 PMCID: PMC4977010 DOI: 10.14639/0392-100x-899] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/28/2015] [Accepted: 12/02/2015] [Indexed: 12/05/2022]
Abstract
Hemifacial spasm is a condition that may severely reduce patients' quality of life. Microvascular decompression is the neurosurgical treatment of choice. The objective of this work was to describe the efficacy and morbidity of microvascular decompression for hemifacial spasm, evaluate the long-term efficacy on the quality of life and investigate prognostic factors for failure of the procedure. A retrospective study of 446 cases of hemifacial spasm treated by 511 retrosigmoid microvascular decompression over 22 years was conducted. Epidemiological, clinical and imaging findings, treatment modalities and outcomes of patients with pre- and postoperative HSF-8 quality of life questionnaire were studied. Success rate was 82% after first surgery and 91.6% after revision surgery. A low rate of perioperative morbidity was found. Facial palsy was mostly transient (5.5% transient and 0.2% permanent) and cochleovestibular deficit was seen in 4.8% of patients. Revision surgery increased nervous lesions (10.6% to 20.7%). Mean quality of life scores were significantly improved from 18 to 2 over 32, evaluated 7.3 years after surgery. Predictive factors of surgical failure were single conflicts (p = 0.041), atypical vasculo-nervous conflicts involving other vessel than postero-inferior cerebellar artery (p = 0.036), such as vein (p = 0.045), and other compression sites than root exit zone (p = 0.027). Retrosigmoid microvascular decompression is a safe and effective treatment of hemifacial spasm. Revision surgery is not to be excluded in case of failure, but does place patients at risk for more complications. Quality of life is improved in the long-term, indicating objective and subjective satisfaction.
Collapse
Affiliation(s)
- M Montava
- Aix Marseille Université, IFSSTA R, LBA, UMR-T 24, Marseille, France;,APHM, Hôpital de la Conception, Service d'Oto-rhino-laryngologie et de Chirurgie cervico-faciale, Marseille, France
| | - V Rossi
- APHM, Hôpital de la Conception, Service d'Oto-rhino-laryngologie et de Chirurgie cervico-faciale, Marseille, France
| | - C L CurtoFais
- Hôpital Saint Musse, Service d'Otorhino- laryngologie et de Chirurgie cervico-faciale, Toulon, France
| | - J Mancini
- Aix Marseille Université, INSERM, IRD, UMR912 SESSTIM, Marseille, France;,APHM, Hôpital de la Timone, BiosTIC, Service Biostatistique et Technologies de l'Information et de la Communication, Marseille, France
| | - J-P Lavieille
- Aix Marseille Université, IFSSTA R, LBA, UMR-T 24, Marseille, France;,APHM, Hôpital de la Conception, Service d'Oto-rhino-laryngologie et de Chirurgie cervico-faciale, Marseille, France
| |
Collapse
|
40
|
Capaccio P, Canzi P, Torretta S, Rossi V, Benazzo M, Bossi A, Vitali C, Cavagna L, Pignataro L. Combined interventional sialendoscopy and intraductal steroid therapy for recurrent sialadenitis in Sjögren's syndrome: Results of a pilot monocentric trial. Clin Otolaryngol 2017; 43:96-102. [DOI: 10.1111/coa.12911] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/07/2017] [Indexed: 12/11/2022]
Affiliation(s)
- P. Capaccio
- ENT Clinic; Department of Biomedical, Surgical and Dental Sciences; University of Milan; Fondazione IRCCS Ca’ Granda Policlinico; Milan Italy
| | - P. Canzi
- Department of Otorhinolaryngology; University of Pavia; IRCCS Policlinico S. Matteo Foundation; Pavia Italy
| | - S. Torretta
- Otolaryngology Unit; Department of Clinical Sciences and Community Health; University of Milan; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico; Milan Italy
| | - V. Rossi
- Department of Otorhinolaryngology; University of Pavia; IRCCS Policlinico S. Matteo Foundation; Pavia Italy
| | - M. Benazzo
- Department of Otorhinolaryngology; University of Pavia; IRCCS Policlinico S. Matteo Foundation; Pavia Italy
| | - A. Bossi
- Branch of Medical Statistics, Biometry and Epidemiology “G. A. Maccacaro”; Department of Clinical Sciences and Community Health; University of Milan; Milan Italy
| | - C. Vitali
- Istituto Villa San Giuseppe; Como Italy
- Casa di Cura di Lecco; Lecco Italy
| | - L. Cavagna
- Division of Rheumatology; University of Pavia; IRCCS Policlinico S. Matteo Foundation; Pavia Italy
| | - L. Pignataro
- Otolaryngology Unit; Department of Clinical Sciences and Community Health; University of Milan; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico; Milan Italy
| |
Collapse
|
41
|
Ghia P, Scarfò L, Coscia M, Sancetta R, Ferrario A, Tedeschi A, Farina L, Laurenti L, Orlandi E, Reda G, Motta M, Carlo Stella C, Massaia M, Quaresmini G, Rossini F, Ladetto M, Gaidano G, Rossi V, Montillo M. A MRD-GUIDED APPROACH FOR THE COMBINATION OF IBRUTINIB TO VENETOCLAX IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (IMPROVE STUDY). Hematol Oncol 2017. [DOI: 10.1002/hon.2440_11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- P. Ghia
- Strategic Program on CLL; IRCCS Ospedale San Raffaele; Milan Italy
| | - L. Scarfò
- Strategic Program on CLL; IRCCS Ospedale San Raffaele; Milan Italy
| | - M. Coscia
- Division of Hematology, University of Torino; AOU Città della Salute e della Scienza di Torino; Torino Italy
| | - R. Sancetta
- U.O.C. Ematologia; Azienda ULSS 3 Serenissima; Mestre Italy
| | - A. Ferrario
- UOC Ematologia; Azienda Socio Sanitaria Territoriale dei Sette Laghi Ospedale di Circolo e Fondazione Macchi; Varese Italy
| | - A. Tedeschi
- Department of Haematology & Oncology Service of Haematology; Niguarda Cancer Center Niguarda Hospital; Milan Italy
| | - L. Farina
- Istituto Nazionale dei Tumori; Unità Trapianto di Midollo; Milan Italy
| | - L. Laurenti
- Policlinico A. Gemelli; Università Cattolica del Sacro Cuore; Rome Italy
| | - E. Orlandi
- S.C Ematologia; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - G. Reda
- UOC Oncoematologia; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico; Milan Italy
| | - M. Motta
- U.O. Ematologia; Spedali Civili di Brescia-Azienda Ospedaliera; Brescia Italy
| | - C. Carlo Stella
- Sezione di Ematologia; Cancer Center Humanitas; Rozzano Italy
| | - M. Massaia
- Struttura Complessa di Ematologia; Azienda Ospedaliera S. Croce e Carle di Cuneo; Cuneo
| | - G. Quaresmini
- Ematologia; Azienda Ospedaliera Papa Giovanni XXIII; Bergamo Italy
| | - F. Rossini
- Divisione di Ematologia e Trapianto di Midollo, Ospedale S. Gerardo; Universita' di Milano Bicocca; Monza Italy
| | - M. Ladetto
- Ematologia; Presidio Ospedaliero SS Antonio e Biagio; Alessandria Italy
| | - G. Gaidano
- Divisione di Ematologia; Università del Piemonte Orientale "Amedeo Avogadro"; Novara Italy
| | - V. Rossi
- Hematology & Transfusion Medicine; L. Sacco University Hospital & School of Medicine; Milan Italy
| | - M. Montillo
- Department of Haematology & Oncology Service of Haematology; Niguarda Cancer Center Niguarda Hospital; Milan Italy
| |
Collapse
|
42
|
Capaccio P, Gaffuri M, Rossi V, Pignataro L. Sialendoscope-assisted transoral removal of hilo-parenchymal sub-mandibular stones: surgical results and subjective scores. Acta Otorhinolaryngol Ital 2017; 37:122-127. [PMID: 28516974 PMCID: PMC5463519 DOI: 10.14639/0392-100x-1601] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/15/2016] [Accepted: 12/12/2016] [Indexed: 11/23/2022]
Abstract
It has been suggested that a conservative trans-oral approach to proximal and hilo-parenchymal submandibular stones (HPSMS) is a valid alternative to the more frequently used sialadenectomy. The aim of this study was to evaluate the surgical, ultrasonographic and patients' subjective outcomes of results of the trans-oral removal of HPSMS. Between January 2003 and September 2015, sialendoscope-assisted trans-oral surgery was used to remove symptomatic, large (> 7 mm), fixed and palpable HPSMS from 479 patients under general anaesthesia. All patients were followed clinically and ultrasonographically to investigate symptom relief and recurrence of stones, and were telephonically interviewed to assess saliva-related subjective outcomes with a questionnaire. Stones were successfully removed from 472 patients (98.5%); the seven failures (1.5%) concerned pure parenchymal stones. One year after the procedure, 408 patients (85.1%) were symptom free, 59 (12.3%) had recurrent obstructive symptoms and 12 (2.6%) had recurrent infections. Of the 54 patients who developed a recurrent stone (11.2%), 52 underwent a second procedure: 29 interventional sialendoscopies, two sialendoscope-assisted intra-corporeal pneumatic lithotripsy, eight secondary transoral surgery to remove residual stones, six a cycle of extra-corporeal lithotripsy and seven submandibular sialadenectomy. Most patients (75.2%) reported mild surgery-related pain. The symptoms of 454 patients (94.8%) improved after adjunctive treatment and, at the end of follow-up, the affected gland was preserved in 98.5% of patients. A sialendoscope-assisted trans-oral removal of large HPSMS is a safe, effective, conservative surgical procedure, and functional preservation of the main duct and parenchyma of the obstructed gland allows sialendoscopic access through the natural ostium in case of recurrence. Combining a trans-oral approach with other minimally invasive, conservative procedures ensures symptomatic relief and salivary duct system clearance in the majority of patients.
Collapse
Affiliation(s)
- P Capaccio
- Department of Otolaryngology and Head and Neck Surgery, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.,Department of Biomedical, Surgical, Dental Sciences
| | - M Gaffuri
- Department of Otolaryngology and Head and Neck Surgery, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - V Rossi
- Department of Otolaryngology and Head and Neck Surgery, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.,Department of Biomedical, Surgical, Dental Sciences
| | - L Pignataro
- Department of Otolaryngology and Head and Neck Surgery, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.,Department of Clinical Sciences and Community Health, University of Milan, Italy
| |
Collapse
|
43
|
Rampinelli G, Pinotti R, Müller A, De Souza F, Rossi V. Eventi avversi in chirurgia parodontale. Dental Cadmos 2017. [DOI: 10.19256/d.cadmos.04.2017.06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
44
|
Viozzi E, Rossi V, Tripodi F, Nimbi F, Simonelli C. PS-03-001 Female sexual pain and quality of sex life: Preliminary results of the Italian protocol “sexuality and well-being”. J Sex Med 2017. [DOI: 10.1016/j.jsxm.2017.03.093] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
45
|
Savary S, Bregaglio S, Willocquet L, Gustafson D, Mason D’Croz D, Sparks A, Castilla N, Djurle A, Allinne C, Sharma M, Rossi V, Amorim L, Bergamin A, Yuen J, Esker P, McRoberts N, Avelino J, Duveiller E, Koo J, Garrett K. Crop health and its global impacts on the components of food security. Food Secur 2017. [DOI: 10.1007/s12571-017-0659-1] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
46
|
Onesti G, González-Domínguez E, Rossi V. Production of Pycnidia and Conidia by Guignardia bidwellii, the Causal Agent of Grape Black Rot, as Affected by Temperature and Humidity. Phytopathology 2017; 107:173-183. [PMID: 27726499 DOI: 10.1094/phyto-07-16-0255-r] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Black rot, caused by the fungus Guignardia bidwellii, is a polycyclic disease affecting grape leaves and berries. In environmentally controlled experiments and in a 3-year field study, the effects of temperature and relative humidity (RH) were assessed on the following growth parameters of G. bidwellii: (i) formation of pycnidia and cirri in grape leaf lesions, (ii) production and germination of conidia, and (iii) length of the period between lesion appearance and pycnidia production. Pycnidia were produced between 5 and 35°C and at 90 to 100% RH but more pycnidia were produced between 20 and 30°C. No pycnidia were produced at RH < 90%. The first pycnidia were produced in approximately 2 days after lesion appearance at ≥20°C and in 8 days at 5°C; pycnidia continued to be produced on the same lesion for 5 to 16 days after lesion appearance, depending on the temperature. Models were developed to describe the effect of temperature and RH on pycnidia production, accounting for 95 and 97% of variability, respectively. Cirri were extruded only between 15 and 35°C and mainly at 100% RH. Field experiments confirmed that pycnidia are produced for several days on a leaf lesion and that the length of the period between lesion appearance and pycnidia production depends on temperature. Overall, the findings showed that production of conidia requires high humidity; under field conditions, some hours at high humidity, which usually occur at nighttime, rather than constant high humidity may be sufficient.
Collapse
Affiliation(s)
- G Onesti
- Department of Sustainable Crop Production, Università Cattolica del Sacro Cuore, Via E. Parmense 84, Piacenza, I-29122, Italy
| | - E González-Domínguez
- Department of Sustainable Crop Production, Università Cattolica del Sacro Cuore, Via E. Parmense 84, Piacenza, I-29122, Italy
| | - V Rossi
- Department of Sustainable Crop Production, Università Cattolica del Sacro Cuore, Via E. Parmense 84, Piacenza, I-29122, Italy
| |
Collapse
|
47
|
Rossi V, Martorella A, Scudieri D, Menozzi P. Seasonal niche partitioning and coexistence of amphimictic and parthenogenetic lineages of Heterocypris barbara (Crustacea: Ostracoda). CAN J ZOOL 2017. [DOI: 10.1139/cjz-2016-0038] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Sympatry of amphimictic and parthenogenetic lineages in species with mixed reproductive systems is rarely observed in nature. On Lampedusa Island (Pelagie Islands, Italy), amphimictic and parthenogenetic lineages of Heterocypris barbara (Gauthier and Brehm, 1928) co-occur in a temporary pond. Their sympatric persistence calls for an ecological differentiation. We investigated the role of seasonal variation of temperature and photoperiod conditions by two different approaches: microcosms set up by inundation of dry sediments from the temporary pond and life-table experiments. Microcosms recreate conditions similar to the field and in their sediments random samples of resting eggs of both amphimictic and parthenogenetic females are stored. Life-table experiments supplied individual-based estimates of survivorship, adult life span, fecundity, and sex ratio in the progeny. We carried out the experiments at 24 °C and a photoperiod of 12 h light (L) : 12 h dark (D) (simulating fall conditions) and at 16 °C and a photoperiod of 10 h L : 14 h D (simulating winter conditions). Males and amphimictic females were the most numerous forms at 24 °C and 12 h L : 12 h D; parthenogenetic females were dominant at 16 °C and 10 h L : 14 h D. Life-table experiments showed that amphimictic forms do not complete development at 16 °C and 10 h L : 14 h D. Our results suggest that sympatry of amphimictic and parthenogenetic females in the field depends on seasonal niche partitioning and the storage effect of resting eggs that allows survival through adverse-season conditions.
Collapse
Affiliation(s)
- V. Rossi
- Department of Life Sciences, University of Parma, Viale G.P. Usberti 11/A, I-43124 Parma, Italy
- Department of Life Sciences, University of Parma, Viale G.P. Usberti 11/A, I-43124 Parma, Italy
| | - A. Martorella
- Department of Life Sciences, University of Parma, Viale G.P. Usberti 11/A, I-43124 Parma, Italy
- Department of Life Sciences, University of Parma, Viale G.P. Usberti 11/A, I-43124 Parma, Italy
| | - D. Scudieri
- Department of Life Sciences, University of Parma, Viale G.P. Usberti 11/A, I-43124 Parma, Italy
- Department of Life Sciences, University of Parma, Viale G.P. Usberti 11/A, I-43124 Parma, Italy
| | - P. Menozzi
- Department of Life Sciences, University of Parma, Viale G.P. Usberti 11/A, I-43124 Parma, Italy
- Department of Life Sciences, University of Parma, Viale G.P. Usberti 11/A, I-43124 Parma, Italy
| |
Collapse
|
48
|
Rampinelli G, Müller A, Corica A, Pinotti R, Rossi V. Il prelievo di tessuto connettivo: indicazioni, tecniche e alternative. Dental Cadmos 2016. [DOI: 10.19256/d.cadmos.09.2016.05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
49
|
Krska R, de Nijs M, McNerney O, Pichler M, Gilbert J, Edwards S, Suman M, Magan N, Rossi V, van der Fels-Klerx H, Bagi F, Poschmaier B, Sulyok M, Berthiller F, van Egmond H. Safe food and feed through an integrated toolbox for mycotoxin management: the MyToolBox approach. WORLD MYCOTOXIN J 2016. [DOI: 10.3920/wmj2016.2136] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
There is a pressing need to mobilise the wealth of knowledge from the international mycotoxin research conductedover the past 25-30 years, and to perform cutting-edge research where knowledge gaps still exist. This knowledgeneeds to be integrated into affordable and practical tools for farmers and food processors along the chain inorder to reduce the risk of mycotoxin contamination of crops, feed and food. This is the mission of MyToolBox – a four-year project which has received funding from the European Commission. It mobilises a multi-actorpartnership (academia, farmers, technology small and medium sized enterprises, food industry and policystakeholders) to develop novel interventions aimed at achieving a significant reduction in crop losses due tomycotoxin contamination. Besides a field-to-fork approach, MyToolBox also considers safe use options ofcontaminated batches, such as the efficient production of biofuels. Compared to previous efforts of mycotoxin reduction strategies, the distinguishing feature of MyToolBox is to provide the recommended measures to theend users along the food and feed chain in a web-based MyToolBox platform (e-toolbox). The project focuseson small grain cereals, maize, peanuts and dried figs, applicable to agricultural conditions in the EU and China. Crop losses using existing practices are being compared with crop losses after novel pre-harvest interventionsincluding investigation of genetic resistance to fungal infection, cultural control (e.g. minimum tillage or cropdebris treatment), the use of novel biopesticides suitable for organic farming, competitive biocontrol treatment and development of novel modelling approaches to predict mycotoxin contamination. Research into post-harvestmeasures includes real-time monitoring during storage, innovative sorting of crops using vision-technology, novelmilling technology and studying the effects of baking on mycotoxins at an industrial scale.
Collapse
Affiliation(s)
- R. Krska
- University of Natural Resources and Life Sciences, Vienna (BOKU), Department of Agrobiotechnology (IFA-Tulln), Center for Analytical Chemistry, Konrad-Lorenz-Str. 20, 3430 Tulln, Austria
| | - M. de Nijs
- RIKILT Wageningen University & Research, Akkermaalsbos 2, 6708 WB Wageningen, the Netherlands
| | - O. McNerney
- Innovacio i Recerca Industrial i Sostenible SL, Avda. Carl Friedrich Gauss 11, 08860 Castelldefels, Spain
| | - M. Pichler
- International Association for Cereal Science and Technology, Marxergasse 2, 1030 Vienna, Austria
| | - J. Gilbert
- FoodLife International Ltd., ODTU Teknokent, Ikizler Binasi No Ara-1 ODTU, Cankaya 06800, Turkey
| | - S. Edwards
- Harper Adams University, Department of Crop and Environment Science, Edgmond, Newport, Shropshire TF10 8NB, United Kingdom
| | - M. Suman
- BARILLA S.p.A., Advanced Laboratory Research, Barilla Research Labs, via Mantova 166, 43122 Parma, Italy
| | - N. Magan
- Cranfield University, Applied Mycology Group, Soil and Agrifood Institute, Cranfield Health, Cranfield, Bedford MK43 0AL, United Kingdom
| | - V. Rossi
- HORTA SRL, via E. Gorra, 29122 Piacenza, Italy
| | - H.J. van der Fels-Klerx
- RIKILT Wageningen University & Research, Akkermaalsbos 2, 6708 WB Wageningen, the Netherlands
| | - F. Bagi
- University of Novi Sad, Faculty of Agriculture, Trg Dositeja Obradovića 8, Novi Sad 21000, Serbia
| | - B. Poschmaier
- University of Natural Resources and Life Sciences, Vienna (BOKU), Department of Agrobiotechnology (IFA-Tulln), Center for Analytical Chemistry, Konrad-Lorenz-Str. 20, 3430 Tulln, Austria
| | - M. Sulyok
- University of Natural Resources and Life Sciences, Vienna (BOKU), Department of Agrobiotechnology (IFA-Tulln), Center for Analytical Chemistry, Konrad-Lorenz-Str. 20, 3430 Tulln, Austria
| | - F. Berthiller
- University of Natural Resources and Life Sciences, Vienna (BOKU), Department of Agrobiotechnology (IFA-Tulln), Center for Analytical Chemistry, Konrad-Lorenz-Str. 20, 3430 Tulln, Austria
| | - H.P. van Egmond
- Retired from RIKILT, Wageningen University & Research, the Netherlands
| |
Collapse
|
50
|
|